Table 1.
Characteristics of Cohort Participants Treated With SOF/VEL±RBV by Genotype, BC Hepatitis Testers Cohort, 2016–2018
| Overall, No. (%) | GT1, No. (%) | GT2, No. (%) | GT3, No. (%) | |
|---|---|---|---|---|
| Total, No. | 2821 | 1076 | 531 | 1072 |
| Birth cohort | ||||
| <1945 | 104 (3.7) | 26 (2.4) | 36 (6.8) | 24 (2.3) |
| 1945–1964 | 1843 (65.3) | 734 (68.2) | 408 (76.9) | 621 (58) |
| 1965–1974 | 525 (18.6) | 200 (18.6) | 64 (12) | 237 (22.1) |
| ≥1975 | 340 (12.4) | 116 (10.8) | 23 (4.4) | 190 (17.7) |
| Age, median (IQR), y | 58 (50–63) | 58 (51–63) | 61 (56–66) | 55 (47–61) |
| Age | ||||
| <50 | 667 (23.7) | 234 (21.7) | 60 (11.3) | 337 (31.4) |
| 50–60 | 1086 (38.5) | 410 (39) | 187 (35.2) | 440 (41) |
| >60 | 1068 (37.8) | 423 (39.3) | 284 (53.5) | 295 (27.5) |
| Sex | ||||
| Female | 1055 (37.4) | 360 (34.3) | 225 (42.4) | 406 (37.9) |
| Male | 1766 (62.6) | 707 (65.7) | 306 (57.6) | 666 (62.1) |
| Ethnicity | ||||
| White | 2555 (90.6) | 1030 (95.7) | 493 (92.8) | 961 (89.7) |
| Others | 266 (9.5) | 46 (4.3) | 38 (7.2) | 111 (10.4) |
| Treatment regimen | ||||
| SOF/VEL | 2543 (90.2) | 976 (90.7) | 500 (94.2) | 934 (87.1) |
| SOF/VEL+RBV | 278 (9.9) | 100 (9.3) | 31 (5.8) | 138 (12.9) |
| HCV treatment experience | 310 (11.0) | 108 (10.1) | 51 (9.6) | 137 (12.8) |
| Cirrhosis | 105 (3.7) | 26 (2.4) | 21 (4.0) | 53 (5.0) |
| Decompensated cirrhosis | 66 (2.3) | 18 (1.7) | 12 (2.3) | 33 (3.1) |
| OST | ||||
| Recent | 630 (22.3) | 226 (21) | 50 (11.1) | 322 (30.1) |
| Past | 168 (5.9) | 60 (5.6) | 25 (4.7) | 78 (7.3) |
| None | 2023 (71.7) | 790 (73.4) | 447 (84.1) | 672 (62.7) |
| HBV | 187 (6.7) | 50 (5.5) | 36 (6.8) | 76 (7.1) |
| HIV | 248 (8.8) | 80 (8.3) | 21 (4) | 123 (11.4) |
| Diabetes | 354 (12.6) | 128 (11.9) | 71 (13.4) | 128 (11.9) |
| History of injecting drugs | 1021 (36.1) | 370 (35.2) | 131 (24.6) | 478 (44.6) |
| Problematic alcohol use | 833 (29.6) | 333 (30.9) | 134 (25.2) | 343 (32) |
| Mental illness | 987 (35) | 376 (34.9) | 150 (29.9) | 423 (39.5) |
| Statin use | 357 (12.6) | 140 (13) | 80 (16.8) | 102 (9.5) |
| Material deprivation | ||||
| Unknown | 34 (1.2) | 15 (1.4) | 5 (1) | 13 (1.2) |
| Q1 (least) | 384 (13.6) | 146 (13.6) | 78 (14.6) | 140 (13) |
| Q2 | 434 (15.4) | 176 (16.4) | 90 (18.7) | 138 (12.9) |
| Q3 | 530 (19.1) | 198 (18.4) | 103 (19.4) | 204 (19) |
| Q4 | 686 (24.4) | 272 (25.2) | 126 (23.7) | 257 (24) |
| Q5 (most) | 744 (26.4) | 260 (25) | 120 (22.6) | 320 (29.9) |
| Social deprivation | ||||
| Unknown | 34 (1.2) | 15 (1.4) | 5 (1) | 13 (1.2) |
| Q1 (least) | 270 (9.9) | 83 (7.7) | 45 (8.5) | 126 (11.7) |
| Q2 | 335 (11.9) | 118 (11) | 78 (14.7) | 112 (10.5) |
| Q3 | 458 (16.3) | 186 (17.3) | 110 (20.8) | 140 (13) |
| Q4 | 628 (22.3) | 248 (23) | 120 (22.6) | 231 (21.6) |
| Q5 (most) | 1087 (38.6) | 426 (39.6) | 173 (32.6) | 450 (42) |
| Elixhauser index | ||||
| 0 | 1223 (43.4) | 464 (43.1) | 243 (45.8) | 435 (40.5) |
| ≥1 | 1598 (56.7) | 612 (56.9) | 288 (54.3) | 637 (59.4) |
Abbreviations: BC, British Columbia; GT, genotype; HBV, hepatitis B virus; HCV, hepatitis C virus; IQR, interquartile range; OST, opioid substitution therapy; OST, opioid substitution therapy; Q, quintile; RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir; y, year.